RMD
ResMed Inc.
Is RMD Halal?
Sleep apnea and respiratory care devices with excellent compliance.
What You Should Know
ResMed develops medical devices for sleep apnea, COPD, and other respiratory conditions. Its March 31, 2026 Form 10-Q reports $8,784.285 million of assets, $664.096 million of interest-bearing debt, $1,660.513 million of cash, $998.837 million of receivables and $1,431.406 million of quarterly revenue. Debt/assets is 7.56%, liquidity/assets is 18.90%, receivables-plus-cash/assets is 30.27% and disclosed interest income, net is 0.86% of revenue; the examined FTSE, MSCI and Malaysia financial ratios pass.
⚠️ Concerns
- •Healthcare and patient-data end uses
- •Residential-care software customers
- •Interest income and hedge-related amounts
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
664.096 / 8,784.285
1,660.513 / 8,784.285
2,659.35 / 8,784.285
12.3 / 1,431.406
- Financial
- Pass
- Overall
- Pass
Debt/assets is 7.56%, liquidity/assets is 18.90%, receivables-plus-cash/assets is 30.27% and disclosed interest income, net is 0.86% of revenue; examined FTSE ratios and core activity pass.
- Financial
- Pass
- Overall
- Pass
Debt/assets, liquidity/assets and receivables-plus-cash/assets are below the examined MSCI total-assets limits; this is not an index-membership claim.
- Financial
- Pass
- Overall
- Pass
Debt/assets and liquidity/assets pass the examined Malaysia limits; this is a calculation against the named ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored; filing-based financial results remain documented.
Business-activity disclosure
ResMed develops sleep-apnea, respiratory-care devices and residential-care software. The core activity is generally permissible.
Limitation: The filing does not classify every healthcare, patient-data or customer end use into a scholar-approved prohibited-revenue numerator.
Purification
ResMed reports $12.3 million of interest income, net, but does not provide a scholar-approved purification percentage or separate prohibited-activity numerator.
Inputs, assumptions and primary sources
- Amounts are USD millions converted from ResMed's March 31, 2026 Form 10-Q values reported in thousands.
- Interest-bearing debt includes $259.928 million of short-term debt and $404.168 million of long-term debt; operating leases are excluded.
- Cash and cash equivalents are $1,660.513 million and no separately identifiable interest-bearing securities are reported in the selected balance-sheet captions.
- Accounts receivable are $998.837 million net; third-quarter net revenue is $1,431.406 million.
- ResMed reports $12.3 million of interest income, net in the quarter; it includes interest and hedge-related amounts and is used as the disclosed-income proxy.
- Sleep, respiratory-care devices and residential-care software are treated as generally permissible; patient, data and customer end uses remain qualitative review items.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →